Developing Standards for Drug Costs In Pharmacoeconomic Studies Task Force

• Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues & Recommendations: A Report of the ISPOR Drug Cost Task Force – Part I
• Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: A Societal Perspective: A Report of the ISPOR Drug Cost Task Force – Part II
• Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: A Managed Care Perspective: A Report of the ISPOR Drug Cost Task Force – Part III
• Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: A Report of the ISPOR Drug Cost Task Force – Part IV
• Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: A Report of the ISPOR Drug Cost Task Force – Part V
• Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An International Perspective: A Report of the ISPOR Drug Cost Task Force – Part VI

• PRO Task Force: Use of Existing Instruments and Their Modification  
  Use of Existing Patient-Reported Outcome (PRO) Instruments and Their Modification: The ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report 

• ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force
  The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report
  
  
• ISPOR Good Research Practices for Retrospective Database Analysis Task Force
• Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Non-Randomized Studies of Treatment Effects Using Secondary Data Sources - Report of The ISPOR Retrospective Database Analysis Task Force – Part I
• Good Research Practices For Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Non-Randomized Studies of Treatment Effects Using Secondary Data Sources - Report of the ISPOR Retrospective Database Analysis Task Force – Part II
• Good Research Practices for Comparative Effectiveness Research: Analytic Methods to Improve Causal Inference From Non-Randomized Studies Of Treatment Effects Using Secondary Data Sources - Report of the ISPOR Retrospective Database Analysis Task Force – Part III
  
  
• ISPOR Good Practices Task Force on Transferability of Economic Data
  Transferability Of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report
  
  
• ISPOR PRO Task Force: Changing Culture or Language of an Application
  Multinational Trials—Recommendations on the Translations Required, Approaches to Using the Same Language in Different Countries, and the Approaches to Support Pooling the Data: The ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Good Research Practices Task Force Report
  
  
• ISPOR ePRO Good Research Practices Task Force
  Recommendations on Evidence Needed to Support Measurement Equivalence Between Electronic and Paper-Based Patient-Reported Outcome (PRO) Measures: ISPOR EPRO Good Research Practices Task Force Report
  
  
• Building A Pragmatic Road Forward: An ISPOR Consensus Development Workshop on the Future of the QALY
• Moving the QALY Forward: Rationale for Change
• QALYs: The Basics
• QALYs: Some Challenges
• A Different Approach to Health State Valuation
• Retaining and Enhancing the QALY
• The Use of QALYs in Clinical and Patient Decision-making: Issues and Prospects
• Towards a Consensus on the QALY
• On the Benefits of Modeling Using QALYs for Societal Resource Allocation: The Model is the Message
• Moving the QALY Forward or Just Stuck in Traffic?

• ISPOR Medication And Compliance Special Interest Group
  Understanding Medication Compliance and Persistence from an Economics Perspective
  
  
• ISPOR New Code of Ethics Task Force
  ISPOR New Code of Ethics Task Force Report

• ISPOR Task Force On Good Research Practices – Budget Impact Analysis
  Principles Of Good Practice For Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices – Budget Impact Analysis) 
  
  
• ISPOR Medication Compliance and Persistence Special Interest Group (MCP)
• A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases
• Methods for Integrating Medication Compliance and Persistence in Pharmacoeconomic Evaluations

• ISPOR Task Force for Translation and Cultural Adaptation
  Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation

• ISPOR Code of Ethics Task Force
  ISPOR Code of Ethics for Researchers Background Article - Report of the ISPOR Task Force on Code of Ethics for Researchers

• SPOR Randomized Clinical Trial Cost-Effectiveness Task Force
  Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report
  
  
• ISPOR Task Force on Use of Pharmacoeconomic/Health Economic Information in Health Care Decision-Making
  Report of The ISPOR Task Force on Use of Pharmacoeconomic/Health Economic Information in Health Care Decision-Making
  
  
• ISPOR Medication and Compliance Special Interest Group
  Medication Compliance Feedback and Monitoring in a Clinical Trial: Predictors and Outcomes

• ISPOR Task Force on Retrospective Databases
  A Checklist for Retrospective Database Studies—Report of the ISPOR Task Force on Retrospective Databases
  
  
• ISPOR Task Force On Good Research Practices Modeling Studies
  Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies

• ISPOR Advisory Panel Meeting and Conference on Pharmacoeconomic Issues
  ISPOR Advisory Panel Meeting and Conference on Pharmacoeconomic Issues Report